Patents by Inventor Tigran Aivazian

Tigran Aivazian has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BTLA fusion protein agonists and uses thereof
    Patent number: 11939367
    Abstract: The present invention is based on the seminal discovery that BTLA agonist fusion proteins modulate an immune response. Specifically, the present invention provides fusion proteins that bind BTLA enhancing BTLA signaling. The present invention further provides methods of treating cancer and immune and inflammatory diseases and disorders with a BTLA agonist fusion protein as described herein.
    Type: Grant
    Filed: March 1, 2021
    Date of Patent: March 26, 2024
    Assignees: Sanford Burnham Prebys Medical Discovery Institute, Pfizer Inc.
    Inventors: Carl F. Ware, John Sedy, Tigran Aivazian, Brian Miller, Natasha K. Crellin
  • BTLA FUSION PROTEIN AGONISTS AND USES THEREOF
    Publication number: 20220025017
    Abstract: The present invention is based on the seminal discovery that BTLA agonist fusion proteins modulate an immune response. Specifically, the present invention provides fusion proteins that bind BTLA enhancing BTLA signaling. The present invention further provides methods of treating cancer and immune and inflammatory diseases and disorders with a BTLA agonist fusion protein as described herein.
    Type: Application
    Filed: March 1, 2021
    Publication date: January 27, 2022
    Inventors: Carl F. WARE, John SEDY, Tigran AIVAZIAN, Brian MILLER, Natasha K. CRELLIN
  • BTLA fusion protein agonists and uses thereof
    Patent number: 10961297
    Abstract: The present invention is based on the seminal discovery that BTLA agonist fusion proteins modulate an immune response. Specifically, the present invention provides fusion proteins that bind BTLA enhancing BTLA signaling. The present invention further provides methods of treating cancer and immune and inflammatory diseases and disorders with a BTLA agonist fusion protein as described herein.
    Type: Grant
    Filed: June 29, 2016
    Date of Patent: March 30, 2021
    Assignees: SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE, PFIZER INC.
    Inventors: Carl F. Ware, John Sedy, Tigran Aivazian, Brian Miller, Natasha K. Crellin
  • BTLA FUSION PROTEIN AGONISTS AND USES THEREOF
    Publication number: 20180170999
    Abstract: The present invention is based on the seminal discovery that BTLA agonist fusion proteins modulate an immune response. Specifically, the present invention provides fusion proteins that bind BTLA enhancing BTLA signaling The present invention further provides methods of treating cancer and immune and inflammatory diseases and disorders with a BTLA agonist fusion protein as described herein.
    Type: Application
    Filed: June 29, 2016
    Publication date: June 21, 2018
    Inventors: Carl F. Ware, John Sedy, Tigran Aivazian, Brian Miller, Natasha K. Crellin
  • Linker peptides and polypeptides comprising same
    Patent number: 9409950
    Abstract: The invention is based, at least in part, on the finding that linker peptides which lack the amino acid sequence GSG reduce or eliminate the addition of posttranslational modifications to the polypeptides which comprise them. More specifically, the novel linker peptides disclosed herein reduce the ability of enzymes to link carbohydrate adducts to polypeptides comprising these linker peptides, e.g., reduce the ability of xylosyltransferase to link xylose to polypeptides. These novel linker peptides, molecules comprising same, and methods of their use are described.
    Type: Grant
    Filed: December 22, 2011
    Date of Patent: August 9, 2016
    Assignee: Biogen MA Inc.
    Inventors: Brian Robert Miller, Scott Glaser, Justin Caravella, Susan Foley, Xiaoping Hronowski, Tigran Aivazian